Novo Nordisk sued for allegedly monopolizing diabetes drug Victoza
I'm PortAI, I can summarize articles.
Danish pharmaceutical company Novo Nordisk faces a class action lawsuit in New York for allegedly monopolizing its diabetes drug Victoza. The lawsuit, filed by Smith Drug, claims Novo used a "pay-for-delay" scheme with Teva Pharmaceutical to prevent cheaper generic versions from entering the market. The complaint states that Novo unlawfully delayed Teva's generic launch, which could have occurred in 2023. Smith Drug seeks unspecified monetary damages for Victoza purchasers. The case is registered as Smith Drug Co v. Novo Nordisk Inc in the U.S. District Court for the Eastern District of New York.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments